Finance entity
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.6. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline.
Last mentioned: Mar 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. At 5, the average consequence score sits below the same-window beat average of 6.6. Source depth averages 2 original sources per story, versus 2.7 across the same-window beat baseline. Vuzix appears in 1 tracked Finance story from March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 128 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vuzix. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings
Both Mineralys and Vuzix report year-end financial results and 2026 guidance.
FDA NDA Acceptance
FDA formally accepts Mineralys Therapeutics' application for Lorundrostat.
PDUFA Goal Date
Expected timeframe for the FDA's final decision on Lorundrostat commercialization.
Mineralys Therapeutics secured a major regulatory win with FDA acceptance of its Lorundrostat NDA, while Vuzix continues to navigate the transition from pilot programs to enterprise-scale AR deployments.
Vuzix is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
